Please Wait...

Cardiovascular Safety in Biopharmaceutical Product Development – From QT Prolongation and Beyond

October 16, 2017 - 11:00am (EDT)

Duration: 60 minutes

Featured Speakers:

The cardiac safety ECG environment continues to mature and expand based on scientific advancements and understanding of pathways and systems associated with generating cardiac risk. The most recent ICH-E14 Q&A, and the ensuing cardiac safety conferences and industry meetings, have highlighted the advancements and direction for evaluating the cardiac safety during the drug development process. In addition to the role of ECG data in cardiac safety assessment, there are also considerations related to the "off-target" blood pressure safety signals, which are a consideration from a safety and regulatory perspective.

Objective

The objective and learning goals for the webinar will include:

  • Provide attendees with the background and perspective on the use of QT prolongation as a cardiac safety endpoint within drug development, and take it forward to the more recent discussions beyond the Through QT (TQT)
  • Learning about additional ECG intervals under discussion related to cardiac safety assessment
  • An overview of the discussion around the use of long term ECG capture versus the 10 second ECG signal/waveform in clinical trials
  • Provide a case study approach looking at therapeutic indications/class of compounds that require specific considerations
  • Present background associated with the focus on BP as a cardiovascular safety endpoint in recent years, specific to the off-target blood pressure signal, using a case study review approach for the discussion

Register Now

Jean T. Barbey, MD, Cardiovascular Safety Expert

Dr. Barbey has more than 20 years of experience as a practicing physician, teacher, and clinical researcher in academia and the contract research organization (CRO) industry. He is a fellow of the American College of Cardiology (FACC) and board-certified in internal medicine, clinical pharmacology, cardiovascular disease, and cardiac electrophysiology. He previously served as the medical director at Medifacts International, (now Bioclinica) a global cardiac core laboratory.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Learn about When EDC is not enough: Automating multi-country data collection and complete workflows at #DIA2019! Ja… https://t.co/zJfytNpz82
Bioclinica (3 days ago)
In San Diego for #DIA2019? Visit us at booth #1831 and meet face to face with our team to learn more about our rapi… https://t.co/T4U4oNXlxo
Bioclinica (2 weeks ago)
We're celebrating International #NASH Day to help raise awareness about non-alcoholic steatohepatitis & fatty liver… https://t.co/16PfGbzeaS
Bioclinica (2 weeks ago)
Global site payments automation in clinical trials. Ck it out! https://t.co/QUEhyRMsN4 https://t.co/pZ0ZUviKuv
Bioclinica (4 weeks ago)
Come talk to #Bioclinica at #ASCO19! See why we're the world leader in #oncology imaging, helping to assess efficac… https://t.co/h0ng6StIbU
Bioclinica (4 weeks ago)
Great insights for sponsors conducting #NAFLD #NASH #clinical trials. https://t.co/TG1WwRhVE8 https://t.co/US2Iobjoyd
Bioclinica (5 weeks ago)

Latest Blogs:

Medical Imaging of Non-Alcoholic Fatty Liver Diseases in Clinical Trials
EDC Provider Selection
Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box